文献速递妇科肿瘤

基因定义的同系卵巢癌类器官平台用于开发联合疗法

Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
PubMed 文献 · Cancer Discov · 2020-11-06

研究利用慢病毒转导和/或CRISPR/Cas9构建小鼠输卵管上皮类器官,模拟高级别浆液性输卵管卵巢癌(HGSC)的突变组合。不同基因型类器官在增殖、分化、分泌组、拷贝数变异和致瘤性上存在差异,并对化疗和免疫微环境有不同反应;基于此开发的化疗/免疫联合方案在Trp53-/-;Ccne1OE;Akt2OE;KrasOE肿瘤中诱导持久T细胞依赖反应,而Trp53-/-;Pten-/-;Nf1-/-肿瘤无反应。

要点

  • 基因定义的同系类器官可模拟HGSC患者突变组合并保留免疫competent微环境。
  • 不同基因型类器官对化疗敏感性及免疫微环境调控存在差异。
  • 化疗/免疫联合方案在CCNE1扩增样模型中有效,在PTEN/NF1缺失模型中无效。

核心结论

  • 基因型信息化的同系类器官平台可用于快速评估肿瘤生物学和治疗方法。
  • 针对CCNE1扩增亚群的化疗/免疫联合方案在特定基因型模型中显示持久T细胞依赖反应。

研究设计与样本

  • 通过慢病毒基因转导和/或CRISPR/Cas9诱变工程化小鼠输卵管上皮类器官,构建多种HGSC模型。
  • 模型涵盖HR proficient(Trp53-/-;Ccne1OE;Akt2OE;KrasOE)、HR deficient(Trp53-/-;Brca1-/-;MycOE)和unclassified(Trp53-/-;Pten-/-;Nf1-/-)基因型。

主要发现

  • 不同基因型类器官在体外增殖、分化、分泌组、拷贝数畸变和致瘤性上存在差异。
  • 致瘤性类器官对HGSC化疗药物敏感性可变,并诱发可被中和类器官产生趋化因子/细胞因子调控的 distinct 免疫微环境。
  • 化疗/免疫联合方案在Trp53-/-;Ccne1OE;Akt2OE;KrasOE肿瘤中产生持久T细胞依赖反应,而Trp53-/-;Pten-/-;Nf1-/-肿瘤无反应。
  • 小鼠和人类HGSC模型在化疗敏感性、分泌组和免疫微环境方面显示基因型依赖的相似性。

临床怎么用

  • 可利用基因型定义的同系类器官平台快速评估肿瘤生物学和候选疗法。
  • 针对CCNE1扩增的HGSC亚群,可考虑化疗/免疫联合策略并在模型中验证T细胞依赖反应。

局限性

  • 研究基于小鼠类器官模型,人类HGSC中的临床转化需进一步验证。
  • 未报告联合方案的具体剂量、给药 schedule 及样本量等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The paucity of genetically informed, immunocompetent tumor models impedes evaluation of conventional, targeted, and immune therapies. By engineering mouse fallopian tube epithelial organoids using lentiviral gene transduction and/or CRISPR/Cas9 mutagenesis, we generated multiple high-grade serous tubo-ovarian cancer (HGSC) models exhibiting mutational combinations seen in patients with HGSC. Detailed analysis of homologous recombination (HR)-proficient (Trp53-/-;Ccne1OE;Akt2OE;KrasOE ), HR-deficient (Trp53-/-;Brca1-/-;MycOE ), and unclassified (Trp53-/-;Pten-/-;Nf1-/- ) organoids revealed differences in in vitro properties (proliferation, differentiation, and "secretome"), copy-number aberrations, and tumorigenicity. Tumorigenic organoids had variable sensitivity to HGSC chemotherapeutics, and evoked distinct immune microenvironments that could be modulated by neutralizing organoid-produced chemokines/cytokines. These findings enabled development of a chemotherapy/immunotherapy regimen that yielded durable, T cell-dependent responses in Trp53-/-;Ccne1OE;Akt2OE;Kras HGSC; in contrast, Trp53-/-;Pten-/-;Nf1-/- tumors failed to respond. Mouse and human HGSC models showed genotype-dependent similarities in chemosensitivity, secretome, and immune microenvironment. Genotype-informed, syngeneic organoid models could provide a platform for the rapid evaluation of tumor biology and therapeutics. SIGNIFICANCE: The lack of genetically informed, diverse, immunocompetent models poses a major barrier to therapeutic development for many malignancies. Using engineered fallopian tube organoids to study the cell-autonomous and cell-nonautonomous effects of specific combinations of mutations found in HGSC, we suggest an effective combination treatment for the currently intractable CCNE1-amplified subgroup.This article is highlighted in the In This Issue feature, p. 211.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zhang S, Iyer S, Ran H, et al. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. Cancer Discov. 2020. PMID: 33158842. doi:10.1158/2159-8290.CD-20-0455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。